PtitStudien: Osteopontin as a Biomarker in Pancreatitis

• Sponsor: Linkoeping University (Other)
• Overall Status: Completed
• CT.gov ID: NCT05882500
• Collaborator: (none)
• Enrollment: 103
• Location: 1
• Actual Duration (Months): 143
• Patients Per Site Per Month: 0.7

Study Details

Study Description

Brief Summary

In the early phase of pancreatits, factors that can give information about the development of severety are still lacking. In this study patients will be included prospectively upon the diagnosis of pancreatits and clinical as well as labarotory and radiological factors will be sampled. The aim is do identifiy factors that may aid in the risk stratification for development of different severity grades of pancreatitis.

Condition or Disease	Intervention/Treatment	Phase
Pancreatitis	Other: No intervention, observation

Detailed Description

In the early phase of pancreatits, factors that can give information about the development of severety are still lacking. In this study patients will be included prospectively upon the diagnosis of pancreatits and clinical as well as labarotory and radiological factors will be sampled. The aim is do identifiy factors that may aid in the risk stratification for development of different severity grades of pancreatitis.

Patients admitted and diagnosed with pancreatitis (according to the Atlanta criteria) will have serial testing of se-osteopontin in addiation to rutine blood work. Computet tomograpy and chest x-ray are mandatory as is blood culture.

Study Design

• Study Type: Observational
• Actual Enrollment: 103 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Osteopontin and Other Potential Biomarkers and Factors Important for Prognosis in Pancreatitis
• Actual Study Start Date: Mar 3, 2011
• Actual Primary Completion Date: Oct 19, 2016
• Actual Study Completion Date: Jan 31, 2023

Arms and Interventions

Arm	Intervention/Treatment
Pancreatits Patients with pancreatitis based ont the Atlanta criteria	Other: No intervention, observation

Outcome Measures

Primary Outcome Measures

1. Se-osteopontin [Within 3 days from diagnosis]

   Se-osteopontin will be measured at admission and on day 2 and 3 of hospital stay. The change over time will be correlated to severety of pancreatitis as classified in the current Atlanta classification.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All

Inclusion Criteria:

• Diagnosis of pancreatitis

Exclusion Criteria:

• Pregnancy, lactation, unable to understand the study

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Linkoping University Hospital	Linköping		Sweden	582 72

Sponsors and Collaborators

• Linkoeping University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Bergthor Björnsson, Associate Professor, Linkoeping University
• ClinicalTrials.gov Identifier: NCT05882500
• Other Study ID Numbers: PtitStudien
• First Posted: May 31, 2023
• Last Update Posted: May 31, 2023
• Last Verified: May 1, 2023

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Pancreatitis

Study Results

No Results Posted as of May 31, 2023